EP2925123A1 - Erythrocyte preservation method - Google Patents
Erythrocyte preservation methodInfo
- Publication number
- EP2925123A1 EP2925123A1 EP13858695.3A EP13858695A EP2925123A1 EP 2925123 A1 EP2925123 A1 EP 2925123A1 EP 13858695 A EP13858695 A EP 13858695A EP 2925123 A1 EP2925123 A1 EP 2925123A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- erythrocyte concentrate
- container
- erythrocyte
- gas
- gas system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 320
- 238000000034 method Methods 0.000 title claims abstract description 95
- 238000004321 preservation Methods 0.000 title description 17
- 239000012141 concentrate Substances 0.000 claims abstract description 267
- 239000007789 gas Substances 0.000 claims abstract description 213
- 238000007710 freezing Methods 0.000 claims abstract description 20
- 230000008014 freezing Effects 0.000 claims abstract description 20
- 229910052724 xenon Inorganic materials 0.000 claims description 47
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 43
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 claims description 40
- 239000004803 Di-2ethylhexylphthalate Substances 0.000 claims description 38
- 239000004014 plasticizer Substances 0.000 claims description 36
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 35
- 239000001301 oxygen Substances 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 238000001816 cooling Methods 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 230000006641 stabilisation Effects 0.000 claims description 7
- 238000011105 stabilization Methods 0.000 claims description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 5
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 5
- 239000004800 polyvinyl chloride Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 238000005086 pumping Methods 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 229920002457 flexible plastic Polymers 0.000 claims 2
- 230000000670 limiting effect Effects 0.000 description 48
- 238000003860 storage Methods 0.000 description 24
- 206010018910 Haemolysis Diseases 0.000 description 22
- 230000008588 hemolysis Effects 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 238000002617 apheresis Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 238000004555 blood preservation Methods 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- DJDSLBVSSOQSLW-UHFFFAOYSA-N mono(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(O)=O DJDSLBVSSOQSLW-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0236—Mechanical aspects
- A01N1/0242—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0236—Mechanical aspects
- A01N1/0263—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving, e.g. cool boxes, blood bags or "straws" for cryopreservation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0289—Pressure processes, i.e. using a designated change in pressure over time
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
Definitions
- the present invention refers to blood preservation method, particularly to the preservation of a donors' blood - namely, packed red blood cells (erythrocyte concentrate).
- the widely used erythrocyte preservation methods involve obtainment of erythrocytes from donors (e.g., using the apheresis method, or by separation from donated whole blood) in the form of packed red blood cells (erythrocyte concentrate) with reduced content of white blood cells and subsequent storage of obtained erythrocyte concentrate in plastic bags at a temperature within the range from 1°C to 6°C for a period of 42 days.
- this method is currently implemented through the use of apheresis apparatuses produced by Haemonetics Corp (Baintree, MA, USA) and Terumo BCT, Inc.
- the red blood cells (RBC) for transfusion are collected from donors into CPD or CP2D anticoagulant preservative solution.
- the RBC are separated by centrifugation method, and a solution for long term storage is added (e.g., AS-3).
- White blood cells are removed by filtration, and the RBC/AS-3 is stored in DEHP plasticized PVC bags at 1-6°C for up to 42 days prior to transfusion.
- DEHP plasticizer has an important protective effect on the RBC, reducing the amount of hemolysis over the course of storage. It is desirable to minimize this storage hemolysis and other storage damage to provide the maximum therapeutic benefit to the transfusion recipient as well as minimize the potential adverse sequelae associated with RBC transfusion.
- the DEHP plasticizer (used for manufacturing such bags) dissolves partially in the erythrocyte concentrate in the course of storage of the RBCs, thereby diffusing from bag material and exerting additional preserving action upon the erythrocytes. It was shown (Dumont Larry J. et al. Exploratory in vitro study of red blood cell storage containers formulated with an alternative plasticizer. Transfusion, 2012 July 52(7): 1439-1445) that the presence of DEHP plasticizer reduces the number of erythrocytes that lysed during the storage of the erythrocyte concentrate.
- DEHP plasticizer in the erythrocyte concentrate decomposes into toxic components, one of which - namely, is mono-ethylhexyl phthalate (MEHP).
- MEHP mono-ethylhexyl phthalate
- a disadvantage of preserving erythrocytes in bags manufactured of material containing DEHP plasticizer is the danger of intoxication of patients after transfusion of a erythrocyte concentrate unit. The indicated negative consequence may increase quite significantly in the case of multiple transfusions. Taking this circumstance into account, it is preferable to store erythrocyte concentrate in bags made of materials that do not contain DEHP plasticizer. Because of theoretical adverse effects in certain high risk patient populations, it is desirable to find an alternative to DEHP as a component in RBC storage bags. However, in this case, the preserving effect (caused by the presence of DEHP plasticizer) is missing, and hence, the number of erythrocytes that lyse during storage increases.
- This method involves obtaining a platelet concentrate from blood obtained from an individual, keeping the platelet plasma in a gas medium containing from 65% to 100% of xenon under pressure from 3.5 to 5 atm, subsequent cooling down of platelet concentrate to a temperature within the range from approximately 1°C to 6°C, and storage under the conditions of the above-indicated temperature and pressure of gas medium. Platelets were obtained by apheresis. This method results in an increase in the storage period for platelets.
- this method for preserving other blood cells (e.g., erythrocytes) is characterized by a number of disadvantages.
- this method presumes the use of a gas mixture, which includes oxygen or atmospheric air in addition to xenon.
- oxygen gases or atmospheric air in addition to xenon.
- hemolysis erythrocytolysis
- Hemolysis of erythrocytes during storage leads to unsatisfactory quality of final product - namely, low number of intact cells in the erythrocyte concentrate, which impairs the efficiency of the latter after transfusion to patients. Even more important are adverse effects of transfusion because of the high hemolysis in the transfused RBC.
- the erythrocyte concentrate In the US, if more than 1% of the erythrocyte concentrate experiences hemolysis, the erythrocyte concentrate is considered unacceptable for blood transfusion. In other countries, the amount of hemolysis must be as low as 0.8% for the erythrocyte concentrate for the erythrocyte concentrate to acceptable for blood transfusion.
- the present invention is directed to an improved method for the preservation of erythrocyte concentrate that ensures storage of the latter for a period of no less than 42 days without considerable degradation of erythrocytes quality and that enables the use of plastic bags manufactured without using DEHP plasticizer.
- the present invention is directed to a blood preservation medicine, and particularly to the preservation of packed red blood cells (erythrocyte concentrate).
- an erythrocyte preservation method with which the erythrocyte concentrate (obtained in advance from the whole blood and placed in a bag) is maintained in a gas system that does not include oxygen gas.
- the gas system includes xenon content that naturally exists in the earth's atmosphere at sea level.
- the gas system includes xenon content that is greater than about 10% by volume.
- the gas system includes xenon content that is greater than about 50% by volume.
- the gas system includes a xenon content from about 65% to about 100% by volume.
- Xenon (Xe) is a noble, inert, elemental gas that is a common component of air at sea level in very small proportions (less than 1/1,000%)). It is unreactive or "inert” under normal biological conditions. Xenon is a readily diffusible gas that is neither utilized nor produced by the body.
- the xenon can optionally be combined with one or more ballast gases (e.g., nitrogen, noble gas, carbon dioxide) at a content from 0%) to 35% by volume.
- the amount of oxygen that is included with the xenon gas or xenon gas and ballast gas mixture is generally less than 5% by volume, typically less than 2% by volume, more typically less than 1% by volume, still more typically less than 0.5% by volume, yet more typically less than 0.1% by volume, and still yet more typically about 0% by volume.
- the amount of xenon in the gas system can be any amount from 65% to 100% by volume (e.g., 65%, 65.1%, 65.2% .... 99.8%, 99.9%, 100%) and can include any range within such values.
- the amount of ballast gas in the gas system can be any amount from 0% to 35% by volume (e.g., 0%, 0.1%, 0.2% .... 34.8%), 34.9%, 35%) and can include any range within such values.
- the ballast gas when used, is generally nitrogen and/or argon; however other inert gasses to the erythrocyte concentrate can be used.
- the gas system is introduced to the erythrocyte concentrate in the container to partially or fully saturate the erythrocyte concentrate with the gas system.
- the erythrocyte concentrate is at least about 75% saturated with the gas system, typically at least about 80% saturated with the gas system, more typically at least about 85% saturated with the gas system, still more typically at least about 90% saturated with the gas system, yet more typically at least about 95% saturated with the gas system, and still yet more typically at least about 98% saturated with the gas system.
- at least a portion of the container is permeable to the gas mixture so that the gas mixture can be introduced into and/or removed from the container via diffusion through the container; however, this is not required.
- the container is in the form of a bag made of polyvinylchloride that may or may not include DEHP plasticizer. The size of the container is non-limiting.
- One non- limiting size is a container that can contain at least 200 ml of erythrocyte concentrate.
- the container is positioned in a hermetically-sealed vessel equipped with a cover that is permeable to the gas mixture.
- the vessel may or may not be permeable to the gas mixture.
- the erythrocyte concentrate in the container can optionally be kept in the presence of the gas mixture and under a pressure above 1 atm without additional pumping of the gas mixture while the container is positioned in the hermetically-sealed chamber.
- the optional cooling of the erythrocyte concentrate in the hermetically-sealed chamber can be started from a moment of gas mixture pressure stabilization in the hermetically sealed chamber, with the stabilization resulting from saturation of erythrocyte concentrate and the gas mixture.
- the pressure of the gas system when the gas system is introduced to the erythrocyte concentrate, is generally no more than about 4 atm. Generally, the pressure of the gas system is at least about 1 atm. For purposes of this invention, atmospheric pressure is 1 atm (760 torr). Generally, the pressure of the gas system is less than about 10 atm.
- the pressure of the gas system when being introduced to the erythrocyte concentrate is about 1 to 4 atm (e.g., 1 atm, 1.1. atm, 1.2 atm .... 3.8 atm, 3.9 atm, 4 atm) and can include any range within such values. In one non- limiting aspect of the invention, the pressure of the gas system when being introduced to the erythrocyte concentrate is greater than atmospheric pressure (e.g., 1 atm).
- the gas system can be introduced to the erythrocyte concentrate when the erythrocyte concentrate is at a temperature that is above the freezing point of the erythrocyte concentrate up to a temperature of about 30C (e.g., O.OrC, 0.02C .... 29.98C, 29.99C, 30C).
- the temperature of the erythrocyte concentrate in a container can be maintained at a constant temperature or be varied (e.g., decreased, increased, etc.) while the gas system is being introduced to the erythrocyte concentrate.
- the gas system is introduced to the erythrocyte concentrate when the erythrocyte concentrate is at a temperature that is up to a temperature of about 25C.
- the gas system is introduced to the erythrocyte concentrate when the erythrocyte concentrate is at a temperature that is up to a temperature of about 23"C. In another non-limiting embodiment, the gas system is introduced to the erythrocyte concentrate when the erythrocyte concentrate is at a temperature that is about 6C to 23X 1.
- the gas system is generally introduced to the erythrocyte concentrate within about 98 hours (e.g., 0.01 hours, 0.02 hours .... 97.98 hours, 97.99 hours, 98 hours) after the blood has been removed from a human or other type of mammal.
- gas system is introduced to the erythrocyte concentrate within about 72 hours after the blood has been removed from a human or other type of mammal.
- gas system is introduced to the erythrocyte concentrate within about 48 hours after the blood has been removed from a human or other type of mammal.
- gas system is introduced to the erythrocyte concentrate within about 24 hours after the blood has been removed from a human or other type of mammal.
- oxygen is removed or purged from the container that includes the erythrocyte concentrate prior to the gas system (i.e., xenon, xenon plus ballast gas) being introduced to the erythrocyte concentrate; however, this is not required.
- the erythrocyte concentrate is exposed to a vacuum environment (e.g., 0 arm, 0.01 atm, 0.02 atm ... 0.97 atm, 0.98 atm, 0.99 atm) for a sufficient period of time (e.g., 0.1 seconds, 0.2 seconds, 0.3 seconds ...
- the degree of the vacuum and the time period that the erythrocyte concentrate is subjected to the vacuum is non-limiting.
- the method of removing or purging the oxygen from the container that includes erythrocyte concentrate also results in the removal of oxygen that is dissolved in the erythrocyte concentrate.
- the erythrocyte concentrate is maintained at a refrigerated temperature (i.e., less than ambient temperature) that is above the freezing point of the erythrocyte concentrate.
- a refrigerated temperature i.e., less than ambient temperature
- the refrigerated temperature is no more than about 25C, typically no more than about 20C, more typically no more than about 1 C, still more typically no more than about IOC, and yet more typically no more than about 6C.
- the erythrocyte concentrate can be maintained at such refrigerated temperature for at least about 42 days and results in hemolysis of the erythrocyte concentrate of no more than about 1%, generally results in hemolysis of the erythrocyte concentrate of no more than about 0.8%, typically results in hemolysis of the erythrocyte concentrate of no more than about 0.7%, and more typically results in hemolysis of the erythrocyte concentrate of no more than about 0.6%.
- the gas system can optionally be introduced to the erythrocyte concentrate more than one time prior to refrigerating the erythrocyte concentrate.
- the erythrocyte concentrate is pressurized with the gas system, then purged of the gas system, and then again pressurized with the gas system.
- the number of pressurizing and purging steps is non-limiting.
- the erythrocyte concentrate is not pressurized, purged and then repressurized more than 5 times, and typically no more than 4 times, more typically no more than 3 times, and still yet more typically no more than 2 times.
- the purging of the gas system from the erythrocyte concentrate can be conducted under a vacuum; however, this is not required.
- the pressurizing of the erythrocyte concentrate with the gas system, then purging of the gas system, and then again pressurizing with the gas system is used to further remove any oxygen remaining in the erythrocyte concentrate after the erythrocyte concentrate was initially purged of air prior to first introducing the gas system to the erythrocyte concentrate.
- the purging of the gas system from the erythrocyte can occur under similar parameters as the removal of the oxygen form the erythrocyte concentrate; however, this is not required.
- the erythrocyte concentrate can be optionally agitated or otherwise shaken to facilitate in the removal of the oxygen from the erythrocyte concentrate.
- the erythrocyte concentrate after being pressurized with the gas system, and prior to and/or during the refrigeration of the erythrocyte concentrate, can optionally be agitated or otherwise shaken to facilitate in the mixing of the gas system with the erythrocyte concentrate.
- the time of agitation can be from about 0.002 hours to 24 hours (e.g., 0.0021 hours, 0.0022 hours ... 23.99 hours, 24 hours). In one non-limiting embodiment, the time of agitation is no more than about 10 hours, typically no more than about 5 hours, and more typically no more than about 3.5 hours.
- the erythrocyte concentrate can optionally be agitated.
- the erythrocyte concentrate is agitated prior to depressurizing the erythrocyte concentrate of the gas system.
- the time of agitation can be from about 0.002 hours to 10 hours (e.g., 0.0021 hours, 0.0022 hours ... 9.99 hours, 9 hours).
- the time of agitation is no more than about 2 hours, typically no more than about 1 hour, more typically no more than about 0.5 hours, and still more typically no more than about 0.2 hours.
- the erythrocyte concentrate is optionally allowed to warm from the refrigerated temperature to ambient temperature (e.g., 25C-27C).
- the time period that the erythrocyte concentrate is allowed to warm can be from about 0.002 hours to 10 hours (e.g., 0.0021 hours, 0.0022 hours ... 9.99 hours, 9 hours). As can be appreciated, longer warming times can be used.
- the erythrocyte concentrate is used in a blood transfusion within about 72 hours, typically within about 36 hours, more typically within about 24 hours, and still more typically within about 12 hours.
- the container used for the erythrocyte concentrate does not include DEHP plasticizer.
- the method of the present invention is able to preserve erythrocyte concentrate for at least about 42 days with hemolysis of the erythrocyte concentrate of no more than about 1% in a container that does not include DEHP plasticizer. Such method is a significant advancement over prior preservation methods that require the preservative effects of DEHP plasticizer to obtain preservation times of 42 days for the erythrocyte concentrate.
- the method of the present invention overcomes this former limitation in the art of preserving erythrocyte concentrate.
- One non-limiting object of the present invention is the provision of a method for preserving an erythrocyte concentrate.
- Another and/or alternative non-limiting object of the present invention is the provision of a method for preserving an erythrocyte concentrate without the use of a container manufactured that includes DEHP plasticizer.
- Still another and/or alternative non-limiting object of the present invention is the provision of a method for preserving an erythrocyte concentrate by use of a gas system that includes xenon gas.
- Yet another and/or alternative non-limiting object of the present invention is the provision of a method for preserving an erythrocyte concentrate by use of a gas system that includes xenon gas and the erythrocyte concentrate has been partially or fully purged of oxygen.
- Still yet another and/or alternative non-limiting object of the present invention is the provision of a method for the preservation of the erythrocyte concentrate that ensures storage of the latter for a period of no less than 42 days without considerable degradation of erythrocytes quality and that enables the use of plastic bags manufactured without using DEHP plasticizer.
- Another and/or alternative non-limiting object of the present invention is the provision of a method for the preservation of the erythrocyte concentrate that reduces hemolysis of the erythrocyte concentrate.
- Still another and/or alternative non-limiting object of the present invention is the provision of a method for the preservation of the erythrocyte concentrate that improves that adenosine triphosphate (ATP) content of the erythrocyte concentrate.
- ATP adenosine triphosphate
- Yet another and/or alternative non-limiting object of the present invention is the provision of an erythrocyte container system designed to preserve erythrocytes that includes a container having an erythrocyte concentrate, and the erythrocyte concentrate in the container is at a temperature of less than ambient temperature, and the erythrocyte concentrate is at least partially saturated with a gas system that includes xenon gas.
- FIG. 1 is a graph that illustrates the degree of hemolysis of a bag of erythrocyte concentrate after 42 days when exposed and not exposed to the gas system of the present invention.
- FIG. 2 is a graph that illustrates the ATP content of a bag of erythrocyte concentrate after
- the present invention is directed to an improved method for the preservation of erythrocyte concentrate.
- the improved method for the preservation of erythrocyte concentrate can be accomplish with or with the use of container manufactured without using DEHP plasticizer.
- the method includes the use of a gas system that is introduced to the erythrocyte concentrate during storage of the erythrocyte concentrate.
- the present invention is also directed to an erythrocyte container system designed to preserving erythrocytes comprising a container that includes an erythrocyte concentrate, and the erythrocyte concentrate is at least partially saturated with a gas system, and the gas system including xenon gas at a concentration that is greater than xenon gas that naturally occurs in the atmosphere.
- erythrocyte concentrate in a container to a gas system that includes xenon gas at a concentration that is greater than xenon gas that naturally occurs in the atmosphere; and,
- the erythrocyte concentrate that has been subjected to the gas system at a temperature that is above the freezing point of the erythrocyte concentrate up to a temperature of about 30C.
- the RBC can be exposed to xenon gas during and/or after the RBC are inserted into the container.
- erythrocyte concentrate in a container to a gas system that includes xenon gas at a concentration of 65% to 100% by volume and optionally includes one or more ballast gases from 0% to 35% by volume; and,
- erythrocyte concentrate in the container to a gas system that includes xenon gas at a concentration that is greater than xenon gas that naturally occurs in the atmosphere after the oxygen removal step; and,
- erythrocyte concentrate in the container Subject the erythrocyte concentrate in the container to a gas system that includes xenon gas at a concentration of 65% to 100% by volume and optionally includes one or more ballast gases from 0% to 35% by volume; and, 4. Maintain the erythrocyte concentrate that has been subjected to the gas system at a temperature that is above the freezing point of the erythrocyte concentrate up to a temperature of about 30C.
- the pressure of the gas system when being introduced to the erythrocyte concentrate in a container is generally less than 6 atm, typically 1-4 atm, more typically 1-3 atm, and still more typically 1 -2 atm.
- the temperature of the erythrocyte concentrate in the container when the gas system is being introduced to the erythrocyte concentrate is generally no greater than about 25C, and typically no greater than about 23 °C.
- the temperature of the erythrocyte concentrate in the container can be maintained at a constant temperature or be varied (e.g., decreased, etc.) while the gas system is being introduced to the erythrocyte concentrate in a container.
- the container that includes the erythrocyte concentrate can optionally be agitated or shaken prior to, during and/or after the gas system is introduced to the erythrocyte concentrate in the container.
- the container that includes the erythrocyte concentrate can be cooled to a temperature of no more than about 6C and greater than the freezing point of the erythrocyte concentrate after the gas system is introduced to the erythrocyte concentrate in the container.
- the container can optionally be absent DEHP plasticizer.
- erythrocyte concentrate in the container to a gas system that includes 65% to 100% by volume xenon and optionally one or more ballast gases from 0% to 35% by volume after the oxygen removal step at a temperature of no more than about 23°C and at a pressure of greater than 1 atm and up to about 4 atm; and
- Method F Obtain an erythrocyte concentrate in a container
- erythrocyte concentrate in a container to a gas system that includes 65% to 100% by volume xenon and optionally one or more ballast gases from 0% to 35% by volume after the oxygen removal step at a temperature of about 18°C to 23°C and at a pressure of about 1.01-2 atm;
- erythrocyte concentrate in a container to a gas system that includes 65%) to 100%) by volume xenon and optionally one or more ballast gases from 0% to 35%o by volume after the oxygen removal step at a temperature of about 18°C to 23°C and at a pressure of about 1.01-2 atm;
- the pressure of the gas system when being introduced to the erythrocyte concentrate in a container is generally less than 6 atm, typically 1-4 atm, more typically 1-3 atm, and still more typically 1 -2 atm.
- the temperature of the erythrocyte concentrate in the container when the gas system is being introduced to the erythrocyte concentrate is generally no greater than about 25C, and typically no greater than about 23 °C.
- the temperature of the erythrocyte concentrate in the container can be maintained at a constant temperature or be varied (e.g., decreased, etc.) while the gas system is being introduced to the erythrocyte concentrate in a container.
- the container that includes the erythrocyte concentrate can optionally be agitated or shaken prior to, during and/or after the gas system is introduced to the erythrocyte concentrate in the container.
- the container that includes the erythrocyte concentrate can be cooled to a temperature of no more than about 6C and greater than the freezing point of the erythrocyte concentrate after the gas system is introduced to the erythrocyte concentrate in the container.
- the container can optionally be absent DEHP plasticizer.
- erythrocyte concentrate including erythrocytes proper
- erythrocyte concentrate is kept in a gas mixture of above- indicated composition under pressure (e.g., 2 atm).
- Saturation of erythrocyte concentrate with xenon under the conditions of above-indicated pressure ensures subsequent storage of the former at a temperature that is above the freezing point and up to about 6C with preservation of viability and functionality of erythrocytes.
- the preserving action of xenon on erythrocytes ensures storage of erythrocyte concentrate for a period of up to 42 days, which allows for giving up the idea of using plastic bags manufactured with the use of DEHP plasticizer.
- the proposed method eliminates diffusion of oxygen from the ambient environment through bag material into the erythrocyte concentrate, which reduces hemolysis of erythrocytes.
- a cooling chamber can optionally be used for cooling the erythrocyte concentrate down and for subsequent storage of cooled erythrocyte concentrate.
- the erythrocyte concentrate can be placed into a container permeable for the gas mixture, and keeping of erythrocyte concentrate in the gas mixture is carried out in a hermetically-sealed chamber, into which the container with erythrocyte concentrate is placed.
- the chamber is vacuumed with the aim to remove oxygen from it.
- a hermetically- sealed vessel equipped with a cover permeable for gas mixture or bag made of material permeable for gas mixture can optionally be used as a container for erythrocyte concentrate.
- the time period during which erythrocyte concentrate is kept in a gas mixture under the pressure is determined by the desired level of erythrocyte concentrate saturation with xenon (as indicated above). For instance, when using a bag made of material permeable for the gas mixture, into which at least 200 ml of erythrocyte concentrate is placed, then subjected to a pressure above 1 atm, this time will be at least about 1 minute, typically less than about 30 hours, more typically at least about 15 minutes, more typically at least about 30 minutes, still more typically at least about 1 hour, and yet still more typically at least about 3 hours.
- duration of keeping the erythrocyte concentrate in a gas mixture under the pressure can be determined based on cessation of gas mixture pressure decrease in the hermetically-sealed chamber (without additional pumping of gas mixture), which indicates on cessation of erythrocyte concentrate saturation with gas mixture components. Cooling the erythrocyte concentrate down can optionally be started from the moment of gas mixture pressure stabilization in the hermetically-sealed chamber.
- the erythrocyte concentrate can optionally be kept under pressure not exceeding atmospheric pressure (1 atmosphere) and at a temperature from 18°C to 28°C (e.g., warm to ambient temperature, etc.) for at least a period that is sufficient for natural heating of erythrocyte concentrate to the above- indicated temperature; however, this is not required.
- the hermetically-sealed chamber can be taken out from the cooling chamber, hermetic sealing is unsealed, and then the bag with erythrocyte concentrate is extracted and kept at room temperature and atmospheric pressure for a time period sufficient for natural heating of erythrocyte concentrate to room temperature and for outgoing of the gas system from erythrocyte concentrate as the erythrocyte concentrate warms to ambient temperature in an environment.
- the container that includes the erythrocyte concentrate can optionally be agitated or shaken and/or be placed under the conditions of decreased pressure or a vacuum (as compared to the atmospheric pressure).
- the present invention could be used in practice for the purpose of preserving erythrocytes
- Standard equipment capable of supplying the gas system into a hermetically- sealed chamber that can withstand the pressure of the gas system of up to 2-4 atm can be used in the present invention.
- Standard refrigerating equipment conventional refrigerators in which preserved blood products are stored can also be used in the present invention.
- the first erythrocyte concentrate is identified by number 2032 and the second erythrocyte concentrate is identified by number 2086.
- Each of the samples was divided into four different containers. Two of the containers for each of the samples included DEHP plasticiser and two of the containers for each of the samples did not include DEHP plasticiser. Also, for each sample, two of the containers included a gas system of 99.9% by volume xenon gas. The graphs indicate which container included or were absent xenon gas and/or DEHP plasticiser.
- the testing protocol for the containers was as follows: For Containers That Are Absent Xe Gas:
- the Xe units and non-Xe units are in the blood bank refrigerator, the Xe units were periodically checked over a 42 day period to ensure that the pressure in the Xe units exceeded 1 atm. After 42 days, all of the units were removed from the blood bank refrigerator. After the units were removed from the blood bank refrigerator, the following procedures where conducted on the units:
- both samples indicated a higher ATP content in the erythrocyte concentrate when treated with xenon gas.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Mechanical Engineering (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22159293.4A EP4032402A1 (en) | 2012-11-30 | 2013-11-19 | Erythrocyte preservation system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261731944P | 2012-11-30 | 2012-11-30 | |
PCT/US2013/070677 WO2014085136A1 (en) | 2012-11-30 | 2013-11-19 | Erythrocyte preservation method |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22159293.4A Division EP4032402A1 (en) | 2012-11-30 | 2013-11-19 | Erythrocyte preservation system |
EP22159293.4A Division-Into EP4032402A1 (en) | 2012-11-30 | 2013-11-19 | Erythrocyte preservation system |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2925123A1 true EP2925123A1 (en) | 2015-10-07 |
EP2925123A4 EP2925123A4 (en) | 2016-06-08 |
EP2925123B1 EP2925123B1 (en) | 2022-08-17 |
Family
ID=50825784
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13858695.3A Active EP2925123B1 (en) | 2012-11-30 | 2013-11-19 | Erythrocyte preservation method |
EP22159293.4A Pending EP4032402A1 (en) | 2012-11-30 | 2013-11-19 | Erythrocyte preservation system |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22159293.4A Pending EP4032402A1 (en) | 2012-11-30 | 2013-11-19 | Erythrocyte preservation system |
Country Status (13)
Country | Link |
---|---|
US (1) | US10123528B2 (en) |
EP (2) | EP2925123B1 (en) |
JP (1) | JP6226438B2 (en) |
KR (1) | KR102101684B1 (en) |
CN (2) | CN104869819A (en) |
AR (1) | AR093615A1 (en) |
BR (1) | BR112015012308B1 (en) |
CA (1) | CA2892006C (en) |
ES (1) | ES2926664T3 (en) |
MX (1) | MX366283B (en) |
RU (1) | RU2632979C2 (en) |
TW (1) | TWI654303B (en) |
WO (1) | WO2014085136A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013049118A1 (en) | 2011-09-26 | 2013-04-04 | Rich Products Corporation | Method for living tissue preservation |
WO2018172422A1 (en) * | 2017-03-21 | 2018-09-27 | Pvac Medical Technologies Ltd | Method of preserving erythrocytes using pvac |
US11629821B1 (en) | 2022-01-19 | 2023-04-18 | Praxair Technology, Inc. | Gas dosing apparatus with directional control valve |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4473552A (en) * | 1981-03-16 | 1984-09-25 | Jost Leonora I | Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells |
US5789151A (en) * | 1997-05-15 | 1998-08-04 | The Regents Of The University Of California | Prolonged cold storage of red blood cells by oxygen removal and additive usage |
US20100196996A1 (en) * | 2009-01-30 | 2010-08-05 | American Air Liquide, Inc. | Process For Preserving Biological Materials For Extended Periods Of Time |
US20120196362A1 (en) * | 2008-07-07 | 2012-08-02 | Ilyin Ilya Y | Method for treatment and storage of platelets |
US20120225416A1 (en) * | 2010-08-25 | 2012-09-06 | Tatsuro Yoshida | Method for enhancing red blood cell quality and survival during storage |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3272969D1 (en) * | 1981-03-16 | 1986-10-09 | Leonora I Jost | Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells |
JPH01171562A (en) * | 1987-12-28 | 1989-07-06 | Terumo Corp | Hemolysis preventing agent |
US4943287A (en) | 1989-07-17 | 1990-07-24 | Miles Inc. | Red blood cell storage system |
US5624794A (en) * | 1995-06-05 | 1997-04-29 | The Regents Of The University Of California | Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas |
US6068148A (en) * | 1998-05-26 | 2000-05-30 | Automatic Liquid Packaging, Inc. | Hermetically sealed container including a nozzle with a sealing bead |
JP2004089495A (en) * | 2002-08-30 | 2004-03-25 | Terumo Corp | Bag link |
-
2013
- 2013-11-19 KR KR1020157014131A patent/KR102101684B1/en active IP Right Grant
- 2013-11-19 CA CA2892006A patent/CA2892006C/en active Active
- 2013-11-19 EP EP13858695.3A patent/EP2925123B1/en active Active
- 2013-11-19 BR BR112015012308A patent/BR112015012308B1/en active IP Right Grant
- 2013-11-19 CN CN201380062534.0A patent/CN104869819A/en active Pending
- 2013-11-19 ES ES13858695T patent/ES2926664T3/en active Active
- 2013-11-19 JP JP2015545089A patent/JP6226438B2/en active Active
- 2013-11-19 WO PCT/US2013/070677 patent/WO2014085136A1/en active Application Filing
- 2013-11-19 MX MX2015006857A patent/MX366283B/en active IP Right Grant
- 2013-11-19 US US14/083,581 patent/US10123528B2/en active Active
- 2013-11-19 CN CN201910934410.6A patent/CN110583627A/en active Pending
- 2013-11-19 RU RU2015125697A patent/RU2632979C2/en active
- 2013-11-19 EP EP22159293.4A patent/EP4032402A1/en active Pending
- 2013-11-27 AR ARP130104353A patent/AR093615A1/en active IP Right Grant
- 2013-11-29 TW TW102143927A patent/TWI654303B/en active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4473552A (en) * | 1981-03-16 | 1984-09-25 | Jost Leonora I | Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells |
US5789151A (en) * | 1997-05-15 | 1998-08-04 | The Regents Of The University Of California | Prolonged cold storage of red blood cells by oxygen removal and additive usage |
US20120196362A1 (en) * | 2008-07-07 | 2012-08-02 | Ilyin Ilya Y | Method for treatment and storage of platelets |
US20100196996A1 (en) * | 2009-01-30 | 2010-08-05 | American Air Liquide, Inc. | Process For Preserving Biological Materials For Extended Periods Of Time |
US20120225416A1 (en) * | 2010-08-25 | 2012-09-06 | Tatsuro Yoshida | Method for enhancing red blood cell quality and survival during storage |
Non-Patent Citations (3)
Title |
---|
LARRY J. DUMONT ET AL: "Exploratory in vitro study of red blood cell storage containers formulated with an alternative plasticizer", TRANSFUSION, vol. 52, no. 7, 30 December 2011 (2011-12-30), pages 1439 - 1445, XP055127658, ISSN: 0041-1132, DOI: 10.1111/j.1537-2995.2011.03506.x * |
None * |
See also references of WO2014085136A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP2925123A4 (en) | 2016-06-08 |
JP2016508120A (en) | 2016-03-17 |
MX366283B (en) | 2019-07-04 |
CA2892006A1 (en) | 2014-06-05 |
TWI654303B (en) | 2019-03-21 |
CN104869819A (en) | 2015-08-26 |
JP6226438B2 (en) | 2017-11-08 |
US10123528B2 (en) | 2018-11-13 |
BR112015012308B1 (en) | 2019-12-17 |
US20140154666A1 (en) | 2014-06-05 |
RU2632979C2 (en) | 2017-10-11 |
AR093615A1 (en) | 2015-06-10 |
BR112015012308A2 (en) | 2017-07-11 |
RU2015125697A (en) | 2017-01-11 |
EP4032402A1 (en) | 2022-07-27 |
WO2014085136A1 (en) | 2014-06-05 |
CN110583627A (en) | 2019-12-20 |
EP2925123B1 (en) | 2022-08-17 |
TW201439320A (en) | 2014-10-16 |
ES2926664T3 (en) | 2022-10-27 |
MX2015006857A (en) | 2016-02-05 |
CA2892006C (en) | 2023-01-24 |
KR20150095636A (en) | 2015-08-21 |
KR102101684B1 (en) | 2020-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5624794A (en) | Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas | |
US5789151A (en) | Prolonged cold storage of red blood cells by oxygen removal and additive usage | |
JP6857291B2 (en) | Long-term storage system for red blood cells and how to use them | |
US6162396A (en) | Blood storage device and method for oxygen removal | |
JP6199557B2 (en) | Blood storage bag system and depletion device with oxygen and carbon dioxide depletion capability | |
US9409128B2 (en) | Methods for storing red blood cell products | |
CA2860037C (en) | Method for living tissue preservation | |
CA2755238A1 (en) | Method for treatment and storage of platelets | |
US10123528B2 (en) | Erythrocyte preservation method | |
JP2005528942A (en) | A long-term storage method of blood and blood components. | |
EP2685815A2 (en) | Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations | |
EP2777727A1 (en) | Methods and systems for processing biological fluids | |
US20130203042A1 (en) | Methods and systems for processing biological fluids | |
MXPA97009537A (en) | Method using elimination of oxygen to extend the useful life in anaquel de celulas sanguineas rojas refrigera |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150522 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20160506 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61J 1/05 20060101ALI20160429BHEP Ipc: C12N 5/07 20100101ALI20160429BHEP Ipc: A01N 1/02 20060101AFI20160429BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RICH TECHNOLOGIES HOLDING COMPANY, LLC Owner name: TRUSTEES OF DARTMOUTH COLLEGE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170407 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20210930 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20220307 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013082354 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1511552 Country of ref document: AT Kind code of ref document: T Effective date: 20220915 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2926664 Country of ref document: ES Kind code of ref document: T3 Effective date: 20221027 |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20220817 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221219 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221217 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013082354 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230530 |
|
26N | No opposition filed |
Effective date: 20230519 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20221130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221130 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20231020 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231019 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231201 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20231023 Year of fee payment: 11 Ref country code: NO Payment date: 20231023 Year of fee payment: 11 Ref country code: IT Payment date: 20231019 Year of fee payment: 11 Ref country code: IE Payment date: 20231023 Year of fee payment: 11 Ref country code: FR Payment date: 20231019 Year of fee payment: 11 Ref country code: DE Payment date: 20231019 Year of fee payment: 11 Ref country code: CH Payment date: 20231201 Year of fee payment: 11 Ref country code: AT Payment date: 20231023 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1511552 Country of ref document: AT Kind code of ref document: T Effective date: 20220817 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20131119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220817 |